Phase 4
N=29
Corticosteroid/Ropivacaine Versus Corticosteroid/Saline Injections for Knee Osteoarthritis
Osteoarthritis
Bottom Line
View on ClinicalTrials.gov: NCT02576249 ↗Enrolled (actual)
29
Serious AEs
0.0%
Results posted
Jul 2017
Primary outcome: Primary: The Knee Osteoarthritis Outcome Score (KOOS) Pain Subscale — 63.1; 67.2 units on a scale
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 4
- Interventions
- Ropivacaine (Drug); Normal saline (Drug); Methylprednisolone (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Mayo Clinic
- Primary completion
- Jul 2016
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY The Knee Osteoarthritis Outcome Score (KOOS) Pain Subscale |
63.1; 67.2 | — |
| SECONDARY Pain Scale Score |
6.4; 5.8; 2.4; 4; 1.9; 2.4 | — |
| SECONDARY Tegner Activity Level Scale |
3.5; 3.0; 4.3; 3.2; 3.5; 3 | — |
Summary
Corticosteroid injections are commonly used for the symptomatic treatment of knee osteoarthritis. Common practice is to inject the joint with a combination of corticosteroid and local anesthetic, with the rationale of providing longer duration pain relief with the corticosteroid and immediate, though short duration relief with the anesthetic. However, multiple in vitro and animal studies have shown that local anesthetic may be harmful to chondrocytes. Despite this data, use of intra-articular anesthetic remains widespread. Many clinicians believe incorporating the anesthetic is important because it can provide immediate pain relief and facilitate patient confidence in the treatment program. However, there is no published data to validate this reasoning. Therefore, the anesthetic has unknown clinical benefit and may have adverse effects on articular cartilage. In light of this, the investigators question the routine use of anesthetics in joint injections. The purpose of this study is to compare the effects of knee joint injections using: 1) corticosteroid with local anesthetic versus 2) corticosteroid with normal saline.
Eligibility Criteria
Inclusion criteria
- Age 18 or older
- Knee osteoarthritis (uni- or bilateral) as defined by the American College of Rheumatology (staged by Kellgren-Lawrence radiographic grading scale)
Exclusion criteria
- Rheumatologic/inflammatory disease
- Metabolic bone disease
- Crystalline arthropathy
- Current smoking
- BMI > 40
- Knee injection with corticosteroid or viscosupplementation within previous 6 months
- History of knee prolotherapy, platelet rich plasma or cellular (stem cell) injection
- Knee surgery within the last year
- Chronic opioid use
- Chronic pain syndrome/fibromyalgia
- Pain behavior during the clinical encounter as judged by the injecting physician
- Physician specifically ordered injection of corticosteroid/anesthetic or other specific combined corticosteroid injection
- Diagnostic uncertainty by referring provider
- Referral for bilateral knee or multiple joint injections (*note that arthritis involving multiple joints alone is not an exclusion criteria, only the patient receiving more than 1 injection)
Data sourced from ClinicalTrials.gov (NCT02576249). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.